CoChat

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

Open access
de Weerdt, Iris, Hofland, Tom, de Boer, Renate, Dobber, Johan A., Dubois, Julie, van Nieuwenhuize, Denise, Mobasher, Mehrdad, de Boer, Fransien, Hoogendoorn, Mels, Velders, Gerjo A., van der Klift, Marjolein, Remmerswaal, Ester B. M., Bemelman, Frederike J., Niemann, Carsten U., Kersting, Sabina, Levin, Mark-David, Eldering, Eric, Tonino, Sanne H., Kater, Arnon P. · 2019 · Blood Advances

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Abstract

Abstract Morbidity and mortality due to immunosuppression remain among the foremost clinical challenges in chronic lymphocytic leukemia (CLL). Although immunosuppression is considered to originate within the lymph node (LN) microenvironment, alterations in T and natural killer (NK) cells have almost exclusively been studied in peripheral blood (PB). Whereas chemoimmunotherapy further deteriorates immune function, novel targeted agents like the B-cell lymphoma 2 inhibitor venetoclax potentially spare nonmalignant lymphocytes; however, the effects of venetoclax on nonleukemic cells have not been explored. We address these unresolved issues using a comprehensive analysis of nonmalignant lymphocytes in paired LN and PB samples from untreated CLL patients, and by analyzing the effects of venetoclax-based treatment regimens on the immune system in PB samples from previously untreated and relapsed/refractory patients. CLL-derived LNs contained twice the amount of suppressive regulatory T cells (Tregs) and CLL supportive follicular T helper (Tfh) cells compared with PB. This was accompanied by a low frequency of cytotoxic lymphocytes. The expression of PD-1 by CD8+ T cells was significantly higher in LN compared with PB. Venetoclax-based treatment led to deep responses in the majority of patients, but also to decreased absolute numbers of B, T, and NK cells. Tfh cell, Treg, and PD-1+ CD8+ T cell numbers were reduced more than fivefold after venetoclax-based therapy, and overproduction of inflammatory cytokines was reduced. Furthermore, we observed restoration of NK cell function. These data support the notion that the immunosuppressive state in CLL is more prominent within the LN. Venetoclax-based regimens reduced the immunosuppressive footprint of CLL, suggesting immune recovery after the elimination of leukemic cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2019000360

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Few cytotoxic lymphocytes in the LN of CLL patients. Lymphocyte analysis in PB and LN samples from untreated CLL patients (PB, n 5 42; LN, n 5 28) and HCs (PB, n 5 10; LN, n 5 5) by flow cytometry. Percentage of CLL (CD5 1 CD19 1 ) cells (A) and T (CD3 1 ) cells (B) within lymphocytes. (C) Ratio of CD4 1 /CD8 1 T cells. Percentage of V d 1 1 cells (D) and V d 2 1 cells (E) within T cells. (F) Percentage of NK (CD56 bright and CD16 1 ) cells within lymphocytes (CLL PB, n 5 21; CLL LN, n 5 5). Data are presented as mean (bar) and individual patients (circles and triangles). * P , .05, ** P , .01, *** P , .001, **** P , . 0001, Wilcoxon matched-pairs signed-rank test (A), 1-way ANOVA followed by Sidak ' s multiple-comparisons test (B-F).
Figure 1 Few cytotoxic lymphocytes in the LN of CLL patients. Lymphocyte analysis in PB and LN samples from untreated CLL patients (PB, n 5 42; LN, n 5 28) and HCs (PB, n 5 10; LN, n 5 5) by flow cytometry. Percentage of CLL (CD5 1 CD19 1 ) cells (A) and T (CD3 1 ) cells (B) within lymphocytes. (C) Ratio of CD4 1 /CD8 1 T cells. Percentage of V d 1 1 cells (D) and V d 2 1 cells (E) within T cells. (F) Percentage of NK (CD56 bright and CD16 1 ) cells within lymphocytes (CLL PB, n 5 21; CLL LN, n 5 5). Data are presented as mean (bar) and individual patients (circles and triangles). * P , .05, ** P , .01, *** P , .001, **** P , . 0001, Wilcoxon matched-pairs signed-rank test (A), 1-way ANOVA followed by Sidak ' s multiple-comparisons test (B-F).CC-BY-NC-ND · From the PDF
Image 2
CC-BY-NC-ND · From the PDF
Figure 3 Depletion of nonmalignant lymphocytes during venetoclax-obinutuzumab treatment. Lymphocyte analysis in PB of patients at baseline (n 5 36), after preinduction with obinutuzumab (n 5 5), and after 1 year of treatment with venetoclax-obinutuzumab (n 5 11) by flow cytometry. Absolute number of B cells (A) and CD4 1 and CD8 1 T cells (B) in PB. (C) Absolute number of NK (CD56 bright and CD16 1 ) cells in PB (baseline, n 5 20). (D) Ratio of CD56 bright (CD56 bright CD16 2 )/CD56 dim (CD56 dim CD16 1 ) cells (baseline, n 5 6). Horizontal lines indicate reference values. * P , .05, ** P , .01, 1-way ANOVA followed by Sidak ' s multiple-comparisons test.
Figure 3 Depletion of nonmalignant lymphocytes during venetoclax-obinutuzumab treatment. Lymphocyte analysis in PB of patients at baseline (n 5 36), after preinduction with obinutuzumab (n 5 5), and after 1 year of treatment with venetoclax-obinutuzumab (n 5 11) by flow cytometry. Absolute number of B cells (A) and CD4 1 and CD8 1 T cells (B) in PB. (C) Absolute number of NK (CD56 bright and CD16 1 ) cells in PB (baseline, n 5 20). (D) Ratio of CD56 bright (CD56 bright CD16 2 )/CD56 dim (CD56 dim CD16 1 ) cells (baseline, n 5 6). Horizontal lines indicate reference values. * P , .05, ** P , .01, 1-way ANOVA followed by Sidak ' s multiple-comparisons test.CC-BY-NC-ND · From the PDF
Figure 4 Tumor-submissive T-cell subsets decrease during venetoclax-obinutuzumab treatment. Lymphocyte analysis in PB of patients at baseline (n 5 11), after preinduction with obinutuzumab (n 5 5), and after 1 year of treatment with venetoclax-obinutuzumab (n 5 11) by flow cytometry. Percentage of Tfh (CXCR5 1 PD-1 1 ) cells (A) and Tregs (CD25 1 FoxP3 1 ) (B) within CD4 1 T cells. (C) Percentage of PD-1 1 cells within CD8 1 T cells. (D) IgG levels in plasma at baseline and after 1 year of venetoclax-obinutuzumab treatment. (E) Cytokine production by CD4 1 T cells after stimulation of PBMCs with PMA/ionomycin for 4 hours. Cytokine production and CD107a expression by CD8 1 T cells (F) and NK cells (G) after stimulation of PBMCs with PMA/ionomycin for 4 hours. * P , .05, ** P , .01, *** P , .001, 1-way ANOVA followed by Sidak ' s multiple-comparisons test.
Figure 4 Tumor-submissive T-cell subsets decrease during venetoclax-obinutuzumab treatment. Lymphocyte analysis in PB of patients at baseline (n 5 11), after preinduction with obinutuzumab (n 5 5), and after 1 year of treatment with venetoclax-obinutuzumab (n 5 11) by flow cytometry. Percentage of Tfh (CXCR5 1 PD-1 1 ) cells (A) and Tregs (CD25 1 FoxP3 1 ) (B) within CD4 1 T cells. (C) Percentage of PD-1 1 cells within CD8 1 T cells. (D) IgG levels in plasma at baseline and after 1 year of venetoclax-obinutuzumab treatment. (E) Cytokine production by CD4 1 T cells after stimulation of PBMCs with PMA/ionomycin for 4 hours. Cytokine production and CD107a expression by CD8 1 T cells (F) and NK cells (G) after stimulation of PBMCs with PMA/ionomycin for 4 hours. * P , .05, ** P , .01, *** P , .001, 1-way ANOVA followed by Sidak ' s multiple-comparisons test.CC-BY-NC-ND · From the PDF
Figure 5 Depletion of nonmalignant lymphocytes when venetoclax is combined with ibrutinib. Lymphocyte analysis in PB of patients at baseline, after preinduction with ibrutinib, and after 1 year of treatment with venetoclax-ibrutinib (n 5 10) by flow cytometry. Absolute number of B cells (A) and CD4 1 and CD8 1 T cells (B) in PB. (C) Absolute number of NK (CD56 bright and CD16 1 ) cells in PB. (D) Ratio of CD56 bright (CD56 bright CD16 2 ) cells vs CD56 dim (CD56 dim CD16 1 ) cells. Horizontal lines indicate reference values. * P , .05, ** P , .01, 1-way ANOVA followed by Sidak ' s multiple-comparisons test.
Figure 5 Depletion of nonmalignant lymphocytes when venetoclax is combined with ibrutinib. Lymphocyte analysis in PB of patients at baseline, after preinduction with ibrutinib, and after 1 year of treatment with venetoclax-ibrutinib (n 5 10) by flow cytometry. Absolute number of B cells (A) and CD4 1 and CD8 1 T cells (B) in PB. (C) Absolute number of NK (CD56 bright and CD16 1 ) cells in PB. (D) Ratio of CD56 bright (CD56 bright CD16 2 ) cells vs CD56 dim (CD56 dim CD16 1 ) cells. Horizontal lines indicate reference values. * P , .05, ** P , .01, 1-way ANOVA followed by Sidak ' s multiple-comparisons test.CC-BY-NC-ND · From the PDF
Figure 6 Fewer Tregs and PD-1 1 CD8 1 T cells after treatment with venetoclax-ibrutinib. Lymphocyte analysis in PB of patients at baseline, after preinduction with ibrutinib, and after 1 year of treatment with venetoclax-ibrutinib (n 5 10) by flow cytometry. Percentage of Tfh (CXCR5 1 PD-1 1 ) cells (A) and Tregs (CD25 1 FoxP3 1 ) (B) within CD4 1 T cells. (C) Percentage of PD-1 1 cells within CD8 1 T cells. (D) IgG levels in plasma at baseline and after 1 year of venetoclax-ibrutinib. (E) Cytokine production by CD4 1 T cells after stimulation of PBMCs with PMA/ionomycin for 4 hours. Cytokine production and CD107a expression by CD8 1 T cells (F) and NK cells (G) after stimulation of PBMCs with PMA/ionomycin for 4 hours. * P , .05, ** P , .01, 1-way ANOVA followed by Sidak ' s multiple-comparisons test.
Figure 6 Fewer Tregs and PD-1 1 CD8 1 T cells after treatment with venetoclax-ibrutinib. Lymphocyte analysis in PB of patients at baseline, after preinduction with ibrutinib, and after 1 year of treatment with venetoclax-ibrutinib (n 5 10) by flow cytometry. Percentage of Tfh (CXCR5 1 PD-1 1 ) cells (A) and Tregs (CD25 1 FoxP3 1 ) (B) within CD4 1 T cells. (C) Percentage of PD-1 1 cells within CD8 1 T cells. (D) IgG levels in plasma at baseline and after 1 year of venetoclax-ibrutinib. (E) Cytokine production by CD4 1 T cells after stimulation of PBMCs with PMA/ionomycin for 4 hours. Cytokine production and CD107a expression by CD8 1 T cells (F) and NK cells (G) after stimulation of PBMCs with PMA/ionomycin for 4 hours. * P , .05, ** P , .01, 1-way ANOVA followed by Sidak ' s multiple-comparisons test.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 111

Metadata

Authors
de Weerdt, I., Hofland, T., de Boer, R., Dobber, J. A., Dubois, J., van Nieuwenhuize, D., Mobasher, M., de Boer, F., Hoogendoorn, M., Velders, G. A., van der Klift, M., Remmerswaal, E. B. M., Bemelman, F. J., Niemann, C. U., Kersting, S., Levin, M.-D., Eldering, E., Tonino, S. H., & Kater, A. P.
Affiliations
  • Department of Hematology, Cancer Center Amsterdam, and
  • Amsterdam University Medical Centers (NL)
  • Cancer Center Amsterdam (NL)
  • Genentech (US)
  • Internal Medicine, Ikazia Hospital, Rotterdam, The Netherlands;
  • Medisch Centrum Leeuwarden (NL)
  • Ziekenhuis Gelderse Vallei (NL)
  • Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands;
  • Renal Transplant Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;
  • Copenhagen University Hospital (DK)
  • Haga Hospital (NL)
  • Albert Schweitzer Ziekenhuis (NL)
Corresponding author
  • Hofland, Tom
  • Tonino, Sanne H.
  • Kater, Arnon P.
Venue
Blood Advances
Published
2019-09-10
Volume
3
Issue
17
Pages
2642-2652
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W2973024487
Cited by
110
References
63
Citations by year
2026: 4 · 2025: 13 · 2024: 14 · 2023: 17 · 2022: 19 · 2021: 24 · 2020: 19
FWCI
8.50
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood Advances (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Novo Nordisk Fonden (NNF16OC0019302)
Topics
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
chronic lymphocytic leukemia, venetoclax, lymph node microenvironment, regulatory T cells, T follicular helper cells, PD-1, CD8+ T cells, natural killer cells, immunosuppression, BCL-2 inhibitor, inflammatory cytokines, immune recovery, relapsed/refractory CLL
MeSH terms
Adult, Aged, Antineoplastic Agents, Blood, Female, Humans, Immune System, Immunosuppression Therapy, Killer Cells, Natural, Lymph Nodes, Lymphocytes, Male, Middle Aged, Sulfonamides, Leukemia, Lymphocytic, Chronic, B-Cell, CD8-Positive T-Lymphocytes, Bridged Bicyclo Compounds, Heterocyclic, T-Lymphocytes, Regulatory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. https://app.cochat.ai/papers/10.1182/bloodadvances.2019000360
The paper
de Weerdt, I., Hofland, T., de Boer, R., Dobber, J. A., Dubois, J., van Nieuwenhuize, D., Mobasher, M., de Boer, F., Hoogendoorn, M., Velders, G. A., van der Klift, M., Remmerswaal, E. B. M., Bemelman, F. J., Niemann, C. U., Kersting, S., Levin, M.-D., Eldering, E., Tonino, S. H., & Kater, A. P. (2019). Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Advances. https://doi.org/10.1182/bloodadvances.2019000360

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.